Who Paid My Doc
Gerald Naccarelli
Cardiovascular Disease Hershey, PA Medical Doctor
NPI 1730137407 CMS profile 214001
500 University Dr, Hershey, PA 17033
General payments
$155,276
Research payments
$8,691
Ownership & investment interest
$0
Research they led as principal investigator
$30,192
Through program year 2025, Gerald Naccarelli of Hershey, PA is reported in the CMS Open Payments database as having received $155,276 across 111 general payments and $8,691 in research payments paid to them. Separately, studies naming them as principal investigator received $30,192 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 97th percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
12 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $5,253 | 1 | |
| 2024 | General | $32 | 3 | |
| 2024 | Research | $300 | 1 | |
| 2023 | General | $4,526 | 16 | |
| 2023 | Research | $1,250 | 1 | |
| 2022 | General | $19,056 | 10 | |
| 2022 | Research | $2,250 | 4 | |
| 2021 | General | $26,582 | 17 | |
| 2020 | General | $44,269 | 24 | |
| 2020 | Research | $643 | 2 | |
| 2019 | General | $55,559 | 40 | |
| 2019 | Research | $4,248 | 6 |
Beside peers
- Gerald Naccarelli
- Cardiovascular Disease median
- Middle half of Cardiovascular Disease
- National median
In program year 2025, general payments to Gerald Naccarelli were reported at $5,253. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.
Show as a table
| Year | Gerald Naccarelli | Cardiovascular Disease median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $55,559 | $450 | $127–$1,392 | $163 |
| 2020 | $44,269 | $242 | $77–$751 | $114 |
| 2021 | $26,582 | $335 | $101–$1,037 | $132 |
| 2022 | $19,056 | $395 | $121–$1,211 | $149 |
| 2023 | $4,526 | $443 | $136–$1,283 | $160 |
| 2024 | $32 | $450 | $136–$1,323 | $164 |
| 2025 | $5,253 | $432 | $132–$1,252 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 10 drugsPart D claims
253
Drug cost
$67,763
Branded share of claims
15.4%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Eliquis Apixaban | Brand | 25 | $40,207 | |
| Xarelto Rivaroxaban | Brand | 14 | $21,406 | |
| Flecainide Acetate | Generic | 44 | $3,323 | |
| Amiodarone Hcl | Generic | 16 | $1,154 | |
| Metoprolol Succinate | Generic | 47 | $1,008 | |
| Atorvastatin Calcium | Generic | 30 | $226 | |
| Losartan Potassium | Generic | 15 | $216 | |
| Furosemide | Generic | 32 | $102 | |
| Amlodipine Besylate | Generic | 18 | $62 | |
| Metoprolol Tartrate | Generic | 12 | $59 |
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,573 Part D prescribers listed as Clinical Cardiac Electrophysiology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 34 billing codesPaid by Medicare
$80,019
Medicare patients
3,075
Services billed
5,664
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Arthritis | 51% | |
| Atrial fibrillation | 45% | |
| Ischemic heart disease | 42% | |
| Heart failure | 36% | |
| Chronic kidney disease | 36% | |
| Diabetes | 35% | |
| Depression | 25% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
125 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Cardiovascular Disease in Pennsylvania
Hemal Gada
Cardiovascular Disease · Wormleysburg, PA
Benjamin Kalsmith
Cardiovascular Disease · Pgh, PA
Peter Kowey
Cardiovascular Disease · Wynnewood, PA
Paul Forfia
Cardiovascular Disease · Philadelphia, PA
Quang Bui
Cardiovascular Disease · Philadelphia, PA
Rhian Davies
Cardiovascular Disease · York, PA
Related records
Cardiovascular Disease in Pennsylvania
Practitioners in the same specialty and state, ranked by reported value.
All Cardiovascular Disease
Everyone recorded under this specialty, nationwide.
Doctors in Pennsylvania
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.